Granules in the improvement of oral heparin bioavailability

International Journal of Pharmaceutics

Volumn 374, Issue 1-2, 2009, Pages 12-16

  Scala Bertola, J ^a   Rabiskova, M ^b   Lecompte, T ^a   Bonneaux, F ^a   Maincent, P ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Anti Xa activity in vivo; Aquacoat ECD; Drug release in vitro; Eudragit RS30D; Granules; Oral heparin delivery

Indexed keywords

BEMIPARIN; ENOXAPARIN; ETHYL CELLULOSE; EUDRAGIT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; ENOXAPARIN; EXCIPIENTS; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; RABBITS; TECHNOLOGY, PHARMACEUTICAL;

EID: 67349154519     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.02.020     Document Type: Article

References (24)

1. Arbit E., Goldberg M., Gomez-Orellana I., and Majuru S. Oral heparin: status review. Thromb. J. 4 (2006) 6
2. Berkowitz S.D., Marder V.J., Kosutic G., and Baughman R.A. Oral heparin administration with a novel drug delivery agent (snac) in healthy volunteers and patients undergoing elective total hip arthroplasty. J. Thromb. Haemost. 1 (2003) 1914-1919
3. Bernkop-Schnurch A., Kast C.E., and Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/gsh systems. J. Control Release 93 (2003) 95-103
4. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: The seventh accp conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 188S-203S
5. Hoffart V., Lamprecht A., Maincent P., Lecompte T., Vigneron C., and Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J. Control Release 113 (2006) 38-42
6. Hoffart V., Ubrich N., Lamprecht A., Bachelier K., Vigneron C., Lecompte T., Hoffman M., and Maincent P. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv. 10 (2003) 1-7
7. Jiao Y., Ubrich N., Hoffart V., Marchand-Arvier M., Vigneron C., Hoffman M., and Maincent P. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J. Pharm. Sci. 91 (2002) 760-768
8. Jiao Y., Ubrich N., Marchand-Arvier M., Vigneron C., Hoffman M., Lecompte T., and Maincent P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105 (2002) 230-235
9. Kim S.K., Lee D.Y., Lee E., Lee Y.K., Kim C.Y., Moon H.T., and Byun Y. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J. Control Release 120 (2007) 4-10
10. Lamprecht A., Koenig P., Ubrich N., Maincent P., and Neumann D. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. Nanotechnology 17 (2006) 3673-3680
11. Lamprecht A., Ubrich N., and Maincent P. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur. J. Pharm. Biopharm. 67 (2007) 632-638
12. Mclean J. The thromboplastic action of cephalin. Am. J. Physiol. 41 (1916) 250-257
13. Motlekar N.A., Fasano A., Wachtel M.S., and Youan B.B. Zonula occludens toxin synthetic peptide derivative at1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin. J. Drug Target 14 (2006) 321-329
14. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J. Drug Target 13 (2005) 573-583
15. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev. Res. 67 (2006) 166-174
16. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Modulation of gastrointestinal permeability of low-molecular-weight heparin by l-arginine: In-vivo and in-vitro evaluation. J. Pharm. Pharmacol. 58 (2006) 591-598
17. Motlekar N.A., and Youan B.B. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J. Control Release 113 (2006) 91-101
18. Rama Prasad Y.V., Minamimoto T., Yoshikawa Y., Shibata N., Mori S., Matsuura A., and Takada K. In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer. Int. J. Pharm. 271 (2004) 225-232
19. Schmitz T., Leitner V.M., and Bernkop-Schnurch A. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. J. Pharm. Sci. 94 (2005) 966-973
20. Teien A.N., and Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin iii. Thromb. Res. 10 (1977) 399-410
21. Thanou M., Henderson S., Kydonieus A., and Elson C. N-sulfonato-n,o-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules. J. Control Release 117 (2007) 171-178
22. Thanou M., Nihot M.T., Jansen M., Verhoef J.C., and Junginger H.E. Mono-n-carboxymethyl chitosan (mcc), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J. Pharm. Sci. 90 (2001) 38-46
23. Thanou M., Verhoef J.C., and Junginger H.E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52 (2001) 117-126
24. Thanou M., Verhoef J.C., Nihot M.T., Verheijden J.H., and Junginger H.E. Enhancement of the intestinal absorption of low molecular weight heparin (lmwh) in rats and pigs using carbopol 934p. Pharm. Res. 18 (2001) 1638-1641